Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) Director Daniel K. Spiegelman sold 3,788 shares of Myriad Genetics stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $22.04, for a total transaction of $83,487.52. Following the sale, the director now directly owns 36,705 shares in the company, […]
SALT LAKE CITY, June 03, 2024 Myriad Genetics, Inc., , a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College.
Artisan Partners Limited Partnership trimmed its position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 4.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,433,377 shares of the company’s stock after selling 103,770 shares during the quarter. […]
Myriad Genetics (NASDAQ:MYGN – Free Report) had its target price increased by Piper Sandler from $23.00 to $28.00 in a research note issued to investors on Monday morning, Benzinga reports. The brokerage currently has a neutral rating on the stock. Several other equities research analysts have also issued reports on MYGN. Leerink Partnrs upgraded shares […]